Comparing the current results to its competitors, Macrogenics Inc reported Revenue increase in the 2 quarter 2026 by 47.62 % year on year. The sales growth was above Macrogenics Inc 's competitors' average revenue growth of 7.1 %, achieved in the same quarter.
Macrogenics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive landscape within the bispecific immuno-oncology sector, particularly targeting PD-1 and CTLA-4 pathways. Competitors with approved or developing treatments in this area include Akeso, Inc., AstraZeneca plc, and Jiangsu Alphamab Biopharmaceuticals Co., Ltd., all of which have substantially greater resources. In the development of antibody-drug conjugate (ADC) therapeutics, competitors include Abbvie Inc., AstraZeneca plc, BeOne Medicines, BioNTech SE, Duality Biotherapeutics, Genmab A/S, GSK plc, Hansoh Pharmaceutical, Innovent Biologics Co., Ltd., MediLink Therapeutics, Merck & Co., Inc., and Pfizer Inc., each possessing significantly greater resources. Additional competition arises from companies developing T-cell engager therapeutics, such as Genentech, Inc., Genmab A/S, Janux Therapeutics, Johnson & Johnson Services, Inc., Regeneron Pharmaceuticals, Inc., Xencor, and Zymeworks, Inc. In the contract development and manufacturing organization (CDMO) market, competition includes full-service contract manufacturers and large pharmaceutical companies offering third-party development and manufacturing services. Some large pharmaceutical companies are divesting manufacturing capacity that may become competitive in the future. Overall, competitors generally have substantially greater financial, marketing, technical, manufacturing, drug development, and human resources. Mergers and acquisitions may further consolidate resources among fewer competitors, while smaller or early-stage companies may also present competition through collaborations with larger firms.
September 21, 2024
A Critical Deadline Approaches: MacroGenics (MGNX) Investors Urged to Act in Pending Class Action Lawsuit SAN FRANCISCO, Sept. 21, 2024 - Hagens Berman Sobol Shapiro LLP, a notable law firm specializing in litigation on behalf of investors, is issuing a critical reminder to investors of MacroGenics, Inc. (NASDAQ: MGNX) regarding the impending class action lawsuit deadline. Investors who have suffered significant financial losses are encouraged to take prompt action before the lead plaintiff deadline of September 24, 2024.The class action lawsuit against MacroGenics stems from alleged misconduct and significant financial discrepancies that may have adversely affected investor portfolios. The nature of thes...
August 3, 2024
In a landscape where investor rights law firms have become key players in corporate accountability, the recent developments surrounding MacroGenics, Inc. (NASDAQ: MGNX) underscore a significant moment for both investors and the biotechnology sector. The renowned Rosen Law Firm has announced the initiation of a class action lawsuit on behalf of shareholders who traded in MacroGenics stock, or engaged in the selling of puts, during a pivotal timeframe from March 7, 2024, to May 9, 2024. The urgency of the matter is clear, as potential lead plaintiffs are required to file their motions by September 24, 2024. Unpacking the AllegationsAt the heart of this lawsuit lies the contention that MacroGenics may have misl...
May 3, 2024
CSIMarket.com aims to provide the latest updates and advancements in the pharmaceutical industry, with a particular focus on breakthrough research and development. In this article, we shed light on the recent financial results announcement made by MacroGenics, Inc., a renowned biopharmaceutical company dedicated to the development, manufacturing, and commercialization of groundbreaking antibody-based therapeutics for cancer treatment. Moreover, we explore the implications of this news for the pharmaceutical industry and the potential impact on patient care.MacroGenics Financial Results for the First Quarter of 2024:MacroGenics, Inc. recently disclosed its financial results for the first quarter of 2024, wh...
Lixte Biotechnology Holdings Inc is a biotech company that focuses on the discovery and development of novel drugs for the treatment of cancer. They primarily operate by conducting pre-clinical and clinical studies, as well as collaborating with research institutions and pharmaceutical companies to advance their drug candidates.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Macrogenics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Macrogenics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
